Anuh Pharma Ltd

- The company currently has no long-term debt and is essentially debt-free except for some pre-shipment facility at low interest (3% to 3.1%). - There is no mention of any current or future fundraising plans through equity or debt in the transcript. - The company is focusing on internal accruals for funding, including CAPEX of around Rs. 4 crores for capacity expansion. - No plans to associate with any Investor Relations (IR) firm for fundraising are indicated. - Overall, the company appears financially stable with no immediate plan for raising funds via debt or equity.

- The company plans to invest an additional ₹4 crores in CAPEX during the current financial year (2021-2022). - This investment aims to increase manufacturing capacity from 1,200 metric tons to 1,500 metric tons by 31st March 2022. - The expansion involves adding a few equipment and machinery to the existing setup; most infrastructure is ready. - The company is actively exploring inorganic expansion opportunities but is waiting for the right candidate or proposal. - They welcome acquisition proposals monthly and will proceed when a suitable target is identified. - The focus is also on backward integration in production, such as making Azithromycin from earlier stages, to reduce dependence on Chinese imports and improve margins.

- The company expects approximately 30% growth in top line and bottom line for FY22, targeting revenue between Rs. 480 to 500 crores. - Current order book as of 1st July 2021 is Rs. 90 crores, indicating good demand. - Q2, Q3, and Q4 sales growth is expected to be similar, driven by conventional products Erythromycin and Pyrazinamide. - New products like Gliclazide are contributing and expected to continue providing higher gross margins. - Capacity utilization stands at 71%, with plans to expand manufacturing capacity from 1,200 to 1,500 metric tons by March 2022, supporting volume growth. - The company is resolving raw material procurement constraints to sustain and improve production and sales. - Regulated market sales contribution is expected to increase, with roughly 10% of the top line potentially coming from the USA by 2025. - New commercial projects with product backward integration (e.g., Azithromycin) nearing completion, expected to add revenue.

- Anuh Pharma expects around 30% growth in both top line and bottom line for FY22, targeting revenues between ₹480 to ₹500 crores. - EBITDA margins are projected to be between 13% to 15%. - Profit before tax margins are expected in the range of 8% to 10%, improving with increasing sales in regulated markets. - Order book as of July 1, 2021, stands at ₹90 crores, indicating strong demand and visibility for growth. - New products like Gliclazide, Ambroxol, Azithromycin, Sulfadoxine contribute to higher margins and sales. - Resolution of raw material procurement issues, especially local sourcing replacing Chinese imports, is expected to support margin recovery. - The company foresees steady capacity utilization improvements with planned capex increasing manufacturing capacity from 1,200 to 1,500 metric tons by March 2022. - By 2025, expects at least 10% of revenues from the US regulated market, supporting higher realizations and profits.

- The order book position as of 1st July 2021 is ₹90 crore. - The company is confident of achieving its top-line and bottom-line targets for the financial year 2022. - There is a pending order status as of 1st July 2021, with good sales of products like Gliclazide, Ambroxol, Azithromycin, and Sulfadoxine. - Some conventional products like Erythromycin and Pyrazinamide had reduced sales due to COVID-19 but are expected to improve. - Raw material procurement issues for one intermediate from China are being resolved with local sourcing expected within 2-3 months to avoid any sales disruptions. - Overall, the company expects similar or continued growth in upcoming quarters (Q2, Q3, and Q4) supported by a current strong order book and resolution of raw material constraints.